Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 11:4:1223657.
doi: 10.3389/falgy.2023.1223657. eCollection 2023.

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis

Marco Dubini  1 , Valentina Benzecry  2 , Federica Rivolta  1 , Andrea Sangalli  1 , Angelo Valerio Marzano  2   3 , Valerio Pravettoni  1 , Simona Tavecchio  3 , Silvia Mariel Ferrucci  2
Affiliations

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis

Marco Dubini et al. Front Allergy. .

Abstract

Introduction: Atopic dermatitis (AD) is considered a systemic type 2 immune driven disease, and it is associated to many atopic comorbidities including asthma. The aim of our study was to prospectively evaluate the respiratory outcomes in patients with persistent allergic asthma treated with dupilumab due to severe AD (sAD).

Methods: We enrolled eligible patients with sAD for dupilumab treatment from September 2018 to December 2020. We then selected the subgroup of patients sensitized to perennial allergens. Dupilumab's efficacy and safety on AD and comorbid asthma were assessed at baseline, one month, four months, and then every 4 months up to one year.

Results: A total of 437 patients with sAD were enrolled for dupilumab treatment due to sAD, and 273 reached 48 weeks of therapy. Respiratory outcomes were evaluated in the 85 asthmatic patients with positivity only to perennial allergens. Our patients showed statistically and clinically significant improvement in asthma control (Asthma Control Test and Asthma Control Questionnaire) and airway obstruction parameters (FEV1), in addition to the expected AD-related skin outcomes. Specifically, a significant improvement was achieved at the fourth month of dupilumab therapy, and this trend was maintained up to twelve months, regardless of asthma severity.

Conclusions: Our results showed the overall improvement of the clinical picture that dupilumab offers for patients with severe AD and persistent allergic asthma of any severity, highlighting the importance of a global multidisciplinary approach of type 2 driven disease.

Keywords: allergic asthma; asthma; atopic comorbidities; atopic dermatitis; dupilumab; multidisciplinarity; type 2 disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. (2020) 396(10247):345–60. 10.1016/S0140-6736(20)31286-1 - DOI - PubMed
    1. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. (2014) 69:17–27. 10.1111/all.12268 - DOI - PubMed
    1. Silverberg JI. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol. (2017) 35:360–6. 10.1016/j.clindermatol.2017.03.008 - DOI - PMC - PubMed
    1. Silverberg NB, Silverberg JI. Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis. (2015) 96:359–61. - PubMed
    1. Hua T, Silverberg JI. Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy. Ann Allergy Asthma Immunol. (2018) 121:622–4. 10.1016/j.anai.2018.07.019 - DOI - PubMed